Details of the Drug Combinations

General Information of This Drug (ID: DMDG8Q3)

Drug Name

Varlitinib DMDG8Q3

Synonyms

VARLITINIB; 845272-21-1; ARRY-334543; ARRY334543; ARRY 334543; ARRY-543; UNII-846Y8197W1; ASLAN-001; 846Y8197W1; (R)-N4-(3-chloro-4-(thiazol-2-ylmethoxy)phenyl)-N6-(4-methyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine; Varlitinib [USAN:INN]; Varlitinib (ARRY334543); Varlitinib free base; Varlitinib (USAN/INN); MLS006011274; GTPL7645; SCHEMBL1384578; CHEMBL2103842; SYN1192; MolPort-028-720-424; EX-A1005; 4-N-[3-chloro-4-(1,3-thiazol-2-ylmethoxy)phenyl]-6-N-[(4R)-4-methyl-4,5-dihydro-1,3-oxazol-2-yl]quinazoline-4,6-diamine

Indication

Disease Entry	ICD 11	Status	REF
Metastatic biliary tract neoplasms	2C14-2C17	Phase 2/3	[1]
Breast cancer	2C60-2C65	Phase 1/2	[2]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

2 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Varlitinib + Capecitabine	DCRK77X	Capecitabine	Advanced or Metastatic Biliary Tract Cancer	[3]
Varlitinib + Capecitabine	DCCY86L	Capecitabine	Biliary Tract Cancer	[4]
------------------------------------------------------------------------------------

References

1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7645).
3	ClinicalTrials.gov (NCT03082053) A Study of Varlitinib in Japanese Subjects With Advanced or Metastatic Solid Tumours
4	ClinicalTrials.gov (NCT03093870) Varlitinib in Combination With Capecitabine for Advanced or Metastatic Biliary Tract Cancer